Other Species / Isoforms
  EphA2 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
Y67-p
NDMPIYMySVCNVMS
0 1
EphA2 (human) NDMPIYMySVCNVMS Y67-p
EphA2 (mouse) DDMPIYMYSVCNVVS Y66
EphA2 (rat) NDMPIYMYSVCNVVS Y66
S113
NSFPGGASSCKETFN
0 1
EphA2 (human) NSFPGGASSCKETFN S113
EphA2 (mouse) NSFPGGAssCKETFN S112-p
EphA2 (rat) NSFPGGASSCKETFN S112
S114
SFPGGASSCKETFNL
0 1
EphA2 (human) SFPGGASSCKETFNL S114
EphA2 (mouse) SFPGGAssCKETFNL S113-p
EphA2 (rat) SFPGGASSCKETFNL S113
K136-ub
DYGTNFQkRLFTkID
0 1
EphA2 (human) DYGTNFQkRLFTkID K136-ub
EphA2 (mouse) DYGTNFQKRQFTKID K135
EphA2 (rat) DYGTNFQKRQFTKID K135
K141-ub
FQkRLFTkIDTIAPD
0 1
EphA2 (human) FQkRLFTkIDTIAPD K141-ub
EphA2 (mouse) FQKRQFTKIDTIAPD K140
EphA2 (rat) FQKRQFTKIDTIAPD K140
S153-p
APDEITVssDFEARH
0 1
EphA2 (human) APDEITVssDFEARH S153-p
EphA2 (mouse) APDEITVSSDFEARN S152
EphA2 (rat) APDEITVSSDFEARN S152
S154-p
PDEITVssDFEARHV
0 1
EphA2 (human) PDEITVssDFEARHV S154-p
EphA2 (mouse) PDEITVSSDFEARNV S153
EphA2 (rat) PDEITVSSDFEARNV S153
K162-ub
DFEARHVkLNVEERS
0 2
EphA2 (human) DFEARHVkLNVEERS K162-ub
EphA2 (mouse) DFEARNVKLNVEERM K161
EphA2 (rat) DFEARNVKLNVEERM K161
S277-p
EDACQACsPGFFKFE
1 0
EphA2 (human) EDACQACsPGFFKFE S277-p
EphA2 (mouse) under review -
EphA2 (rat) under review -
S373-p
CEQCWPEsGECGPCE
0 1
EphA2 (human) CEQCWPEsGECGPCE S373-p
EphA2 (mouse) CEQCWPESGECGPCE S374
EphA2 (rat) CEQCWPESGECGSCE S374
N407
SDLEPHMNYTFTVEA
0 1
EphA2 (human) SDLEPHMNYTFTVEA N407
EphA2 (mouse) SDLEPHMnYTFAVEA N408-ng
EphA2 (rat) SDLEPHMNYTFTVEA N408
S426-p
SGLVTSRsFRtASVs
0 1
EphA2 (human) SGLVTSRsFRtASVs S426-p
EphA2 (mouse) SGLVTSRSFRTASVS S427
EphA2 (rat) SDLVNSRSFRTASVS S427
T429-p
VTSRsFRtASVsINQ
1 0
EphA2 (human) VTSRsFRtASVsINQ T429-p
EphA2 (mouse) under review -
EphA2 (rat) under review -
S433-p
sFRtASVsINQtEPP
0 1
EphA2 (human) sFRtASVsINQtEPP S433-p
EphA2 (mouse) SFRTASVSInQTEPP S434
EphA2 (rat) SFRTASVSINQTEPP S434
N435
RtASVsINQtEPPKV
0 1
EphA2 (human) RtASVsINQtEPPKV N435
EphA2 (mouse) RTASVSInQTEPPKV N436-ng
EphA2 (rat) RTASVSINQTEPPKV N436
T437-p
ASVsINQtEPPKVRL
0 1
EphA2 (human) ASVsINQtEPPKVRL T437-p
EphA2 (mouse) ASVSInQTEPPKVRL T438
EphA2 (rat) ASVSINQTEPPKVRL T438
S570-p
KNQRARQsPEDVyFs
Upstream
0 22
Treatment
  • nocodazole
  • thymidine
EphA2 (human) KNQRARQsPEDVyFs S570-p
EphA2 (mouse) RNLRARQsSEDVRFS S571-p
EphA2 (rat) RNLRARQsSEDVYFS S571-p
Y575-p
RQsPEDVyFsksEQL
Upstream
1 357
Phosphatases, in vitro:
  • ACP1 (human)
Putative in vivo kinases:
  • EphA2 (human)
Regulatory protein:
  • CSFR (human)
  • EGFR (human)
Treatment
  • EGF
  • nocodazole
  • Su11274
  • thymidine
EphA2 (human) RQsPEDVyFsksEQL Y575-p
EphA2 (mouse) RQsSEDVRFSksEQL R576
EphA2 (rat) RQsSEDVYFSKSEQL Y576
S577-p
sPEDVyFsksEQLkP
0 5
EphA2 (human) sPEDVyFsksEQLkP S577-p
EphA2 (mouse) sSEDVRFSksEQLkP S578
EphA2 (rat) sSEDVYFSKSEQLKP S578
K578-ub
PEDVyFsksEQLkPL
0 9
EphA2 (human) PEDVyFsksEQLkPL K578-ub
EphA2 (mouse) SEDVRFSksEQLkPL K579-ub
EphA2 (rat) SEDVYFSKSEQLKPL K579
S579-p
EDVyFsksEQLkPLk
Upstream
0 6
Treatment
  • nocodazole
  • thymidine
EphA2 (human) EDVyFsksEQLkPLk S579-p
EphA2 (mouse) EDVRFSksEQLkPLK S580-p
EphA2 (rat) EDVYFSKSEQLKPLK S580
K583-ub
FsksEQLkPLktyVD
0 10
EphA2 (human) FsksEQLkPLktyVD K583-ub
EphA2 (mouse) FSksEQLkPLKtyVD K584-ub
EphA2 (rat) FSKSEQLKPLKTYVD K584
K586-ub
sEQLkPLktyVDPHt
0 1
EphA2 (human) sEQLkPLktyVDPHt K586-ub
EphA2 (mouse) sEQLkPLKtyVDPHt K587
EphA2 (rat) SEQLKPLKTYVDPHT K587
T587-p
EQLkPLktyVDPHty
Upstream
0 85
Treatment
  • FGF2
EphA2 (human) EQLkPLktyVDPHty T587-p
EphA2 (mouse) EQLkPLKtyVDPHty T588-p
EphA2 (rat) EQLKPLKTYVDPHTY T588
Y588-p
QLkPLktyVDPHtyE
Upstream
Downstream
6 670
EphA2 (human)
Y588-p
EphA2 (mouse)
Y589-p
EphA2 (rat)
Y589-p
Effects on Modified Protein
  • enzymatic activity, induced
  • molecular association, regulation
Effects on Biological Processes:
  • cell adhesion, altered
  • cell differentiation, altered
  • cell motility, altered
Kinase, in vitro:
  • EphA2 (human)
Phosphatases, in vitro:
  • ACP1 (human)
Putative in vivo kinases:
  • EphA2 (human)
Regulatory protein:
  • CSFR (human)
Treatment
  • ALW-II-41-27
  • ephrin_A1
  • ephrin_B1
  • ephrin_B2
  • gefitinib
  • HGF
  • Su11274
EphA2 (human) QLkPLktyVDPHtyE Y588-p
EphA2 (mouse) QLkPLKtyVDPHtyE Y589-p
EphA2 (rat) QLKPLKTYVDPHTYE Y589
T593-p
ktyVDPHtyEDPNQA
Upstream
0 161
Regulatory protein:
  • CSFR (human)
EphA2 (human) ktyVDPHtyEDPNQA T593-p
EphA2 (mouse) KtyVDPHtyEDPNQA T594-p
EphA2 (rat) KTYVDPHTYEDPNQA T594
Y594-p
tyVDPHtyEDPNQAV
Upstream
Downstream
3 776
EphA2 (human)
Y594-p
EphA2 (mouse)
Y595-p
EphA2 (rat)
Y595-p
Effects on Modified Protein
  • enzymatic activity, induced
  • molecular association, regulation
Effects on Biological Processes:
  • cell differentiation, altered
  • cell motility, altered
Kinase, in vitro:
  • EphA2 (human)
Phosphatases, in vitro:
  • ACP1 (human)
Putative in vivo kinases:
  • EphA2 (human)
Regulatory protein:
  • CSFR (human)
  • EGFR (human)
Treatment
  • ephrin_A1
  • ephrin_B1
  • ephrin_B2
  • FGF2
  • gefitinib
  • HGF
  • Su11274
EphA2 (human) tyVDPHtyEDPNQAV Y594-p
EphA2 (mouse) tyVDPHtyEDPNQAV Y595-p
EphA2 (rat) TYVDPHTYEDPNQAV Y595
K603-ub
DPNQAVLkFTTEIHP
0 3
EphA2 (human) DPNQAVLkFTTEIHP K603-ub
EphA2 (mouse) DPNQAVLkFTTEIHP K604-ub
EphA2 (rat) DPNQAVLKFTTEIHP K604
K617-ub
PSCVTRQkVIGAGEF
0 8
EphA2 (human) PSCVTRQkVIGAGEF K617-ub
EphA2 (mouse) PSCVARQkVIGAGEF K618-ub
EphA2 (rat) PSCVSRQKVIGAGEF K618
Y628-p
AGEFGEVykGMLKTS
Upstream
0 52
Putative in vivo kinases:
  • EphA2 (human)
EphA2 (human) AGEFGEVykGMLKTS Y628-p
EphA2 (mouse) AGEFGEVyKGTLKAS Y629-p
EphA2 (rat) AGEFGEVYKGTLKSS Y629
K629-ub
GEFGEVykGMLKTSS
0 1
EphA2 (human) GEFGEVykGMLKTSS K629-ub
EphA2 (mouse) GEFGEVyKGTLKASS K630
EphA2 (rat) GEFGEVYKGTLKSSS K630
K639-ub
LKTSSGKkEVPVAIk
0 2
EphA2 (human) LKTSSGKkEVPVAIk K639-ub
EphA2 (mouse) LKASSGKKEIPVAIK K640
EphA2 (rat) LKSSSGKKEIPVAIK K640
K639
LKTSSGKKEVPVAIk
0 1
EphA2 (human) LKTSSGKKEVPVAIk K639
EphA2 (mouse) LKASSGKKEIPVAIK K640
EphA2 (rat) LKSSSGKkEIPVAIK K640-ac
K646-ub
kEVPVAIktLkAGYT
0 1
EphA2 (human) kEVPVAIktLkAGYT K646-ub
EphA2 (mouse) KEIPVAIKTLKAGYT K647
EphA2 (rat) kEIPVAIKTLKAGYT K647
T647-p
EVPVAIktLkAGYTE
Upstream
0 5
Treatment
  • nocodazole
  • thymidine
EphA2 (human) EVPVAIktLkAGYTE T647-p
EphA2 (mouse) EIPVAIKTLKAGYTE T648
EphA2 (rat) EIPVAIKTLKAGYTE T648
K649-ub
PVAIktLkAGYTEkQ
0 2
EphA2 (human) PVAIktLkAGYTEkQ K649-ub
EphA2 (mouse) PVAIKTLKAGYTEKQ K650
EphA2 (rat) PVAIKTLKAGYTEKQ K650
K655-ub
LkAGYTEkQRVDFLG
0 1
EphA2 (human) LkAGYTEkQRVDFLG K655-ub
EphA2 (mouse) LKAGYTEKQRVDFLS K656
EphA2 (rat) LKAGYTEKQRVDFLS K656
Y685-p
LEGVISKykPMMIIt
0 2
EphA2 (human) LEGVISKykPMMIIt Y685-p
EphA2 (mouse) LEGVVSKYKPMMIIT Y686
EphA2 (rat) LEGVVSKYKPMMIIT Y686
K686-ub
EGVISKykPMMIItE
0 2
EphA2 (human) EGVISKykPMMIItE K686-ub
EphA2 (mouse) EGVVSKYKPMMIITE K687
EphA2 (rat) EGVVSKYKPMMIITE K687
T692-p
ykPMMIItEyMENGA
0 2
EphA2 (human) ykPMMIItEyMENGA T692-p
EphA2 (mouse) YKPMMIITEYMENGA T693
EphA2 (rat) YKPMMIITEYMENGA T693
Y694-p
PMMIItEyMENGALD
Upstream
0 18
Putative in vivo kinases:
  • EphA2 (human)
EphA2 (human) PMMIItEyMENGALD Y694-p
EphA2 (mouse) PMMIITEYMENGALD Y695
EphA2 (rat) PMMIITEYMENGALD Y695
S712-p
REKDGEFsVLQLVGM
0 1
EphA2 (human) REKDGEFsVLQLVGM S712-p
EphA2 (mouse) REKDGEFSVLQLVGM S713
EphA2 (rat) REKDGEFSVLQLVGM S713
K728-ub
RGIAAGMkYLANMNy
0 1
EphA2 (human) RGIAAGMkYLANMNy K728-ub
EphA2 (mouse) RGIASGMKYLANMNy K729
EphA2 (rat) RGIASGMKYLANMNY K729
Y735-p
kYLANMNyVHRDLAA
Upstream
Downstream
1 21
Effects on Modified Protein
  • molecular association, regulation
Effects on Biological Processes:
  • cell differentiation, altered
  • cell motility, altered
Kinase, in vitro:
  • EphA2 (human)
Putative in vivo kinases:
  • EphA2 (human)
Treatment
  • ephrin_A1
EphA2 (human) kYLANMNyVHRDLAA Y735-p
EphA2 (mouse) KYLANMNyVHRDLAA Y736-p
EphA2 (rat) KYLANMNYVHRDLAA Y736
S761-p
KVSDFGLsRVLEDDP
0 3
EphA2 (human) KVSDFGLsRVLEDDP S761-p
EphA2 (mouse) KVSDFGLsRVLEDDP S762-p
EphA2 (rat) KVSDFGLSRVLEDDP S762
T771-p
LEDDPEAtyttsGGk
0 34
EphA2 (human) LEDDPEAtyttsGGk T771-p
EphA2 (mouse) LEDDPEAtyTtsGGK T772-p
EphA2 (rat) LEDDPEATyTTSGGK T772
Y772-p
EDDPEAtyttsGGkI
Upstream
2 910
EphA2 (human)
Y772-p
EphA2 (mouse)
Y773-p
EphA2 (rat)
Y773-p
Kinase, in vitro:
  • EphA2 (human)
Phosphatases, in vitro:
  • ACP1 (human)
Putative in vivo kinases:
  • EphA2 (human)
Regulatory protein:
  • CSFR (human)
  • EGFR (human)
  • FGFR1 (human)
Treatment
  • dasatinib
  • EGF
  • ephrin_A1
  • ephrin_B1
  • ephrin_B2
  • FGF2
  • HGF
  • MG132
  • MG132_withdrawal
  • Su11274
EphA2 (human) EDDPEAtyttsGGkI Y772-p
EphA2 (mouse) EDDPEAtyTtsGGKI Y773-p
EphA2 (rat) EDDPEATyTTSGGKI Y773-p
T773-p
DDPEAtyttsGGkIP
0 24
EphA2 (human) DDPEAtyttsGGkIP T773-p
EphA2 (mouse) DDPEAtyTtsGGKIP T774
EphA2 (rat) DDPEATyTTSGGKIP T774
T774-p
DPEAtyttsGGkIPI
0 19
EphA2 (human) DPEAtyttsGGkIPI T774-p
EphA2 (mouse) DPEAtyTtsGGKIPI T775-p
EphA2 (rat) DPEATyTTSGGKIPI T775
S775-p
PEAtyttsGGkIPIR
0 3
EphA2 (human) PEAtyttsGGkIPIR S775-p
EphA2 (mouse) PEAtyTtsGGKIPIR S776-p
EphA2 (rat) PEATyTTSGGKIPIR S776
K778-ub
tyttsGGkIPIRWTA
0 7
EphA2 (human) tyttsGGkIPIRWTA K778-ub
EphA2 (mouse) tyTtsGGKIPIRWTA K779
EphA2 (rat) TyTTSGGKIPIRWTA K779
S790-p
WTAPEAIsyRKFTSA
0 1
EphA2 (human) WTAPEAIsyRKFTSA S790-p
EphA2 (mouse) WTAPEAISYRKFTSA S791
EphA2 (rat) WTAPEAISYRKFTSA S791
Y791-p
TAPEAIsyRKFTSAS
0 8
EphA2 (human) TAPEAIsyRKFTSAS Y791-p
EphA2 (mouse) TAPEAISYRKFTSAS Y792
EphA2 (rat) TAPEAISYRKFTSAS Y792
K828-sm
LSNHEVMkAINDGFR
0 1
EphA2 (human) LSNHEVMkAINDGFR K828-sm
EphA2 (mouse) LSNHEVMKAINDGFR K829
EphA2 (rat) LSNHEVMKAINDGFR K829
S869-p
PKFADIVsILDkLIR
0 1
EphA2 (human) PKFADIVsILDkLIR S869-p
EphA2 (mouse) PKFADIVSILDkLIR S870
EphA2 (rat) PKFADIVSILDKLIR S870
K873-ub
DIVsILDkLIRAPDs
0 2
EphA2 (human) DIVsILDkLIRAPDs K873-ub
EphA2 (mouse) DIVSILDkLIRAPDS K874-ub
EphA2 (rat) DIVSILDKLIRAPDS K874
S880-p
kLIRAPDsLkTLADF
0 1
EphA2 (human) kLIRAPDsLkTLADF S880-p
EphA2 (mouse) kLIRAPDSLkTLADF S881
EphA2 (rat) KLIRAPDSLKTLADF S881
K882-ub
IRAPDsLkTLADFDP
0 3
EphA2 (human) IRAPDsLkTLADFDP K882-ub
EphA2 (mouse) IRAPDSLkTLADFDP K883-ub
EphA2 (rat) IRAPDSLKTLADFDP K883
S892-p
ADFDPRVsIRLPsts
Upstream
1 71
Treatment
  • EGF
  • Su11274
EphA2 (human) ADFDPRVsIRLPsts S892-p
EphA2 (mouse) ADFDPRVsIRLPsts S893-p
EphA2 (rat) ADFDPRVSIRLPSTS S893
S897-p
RVsIRLPstsGsEGV
Upstream
Downstream
5 202
EphA2 (human)
S897-p
EphA2 (mouse)
S898-p
EphA2 (rat)
S898-p
Effects on Modified Protein
  • intracellular localization
Effects on Biological Processes:
  • carcinogenesis, induced
  • cell motility, altered
  • cell motility, induced
  • cytoskeletal reorganization
Kinase, in vitro:
  • p90RSK (human)
  • RSK2 (human)
Putative in vivo kinases:
  • Akt1 (human)
  • p90RSK (human)
  • RSK2 (human)
Regulatory protein:
  • TAK1 (human)
  • TBK1 (human)
Treatment
  • ALW-II-41-27
  • angiotensin_2
  • BI-D1870
  • crizotinib
  • EGF
  • ephrin_A1
  • FGF2
  • gefitinib
  • HGF
  • ischemia
  • LPA
  • LY294002
  • metastatic potential
  • MG132
  • MK-2206
  • PD166866
  • PDGF
  • phorbol_ester
  • SB202190
  • selumetinib
  • serum
  • Su11274
  • SU5402
  • TNF
  • U0126
  • vemurafenib
EphA2 (human) RVsIRLPstsGsEGV S897-p
EphA2 (mouse) RVsIRLPstsGsEGV S898-p
EphA2 (rat) RVSIRLPSTSGSEGV S898
T898-p
VsIRLPstsGsEGVP
Upstream
0 63
Treatment
  • Su11274
EphA2 (human) VsIRLPstsGsEGVP T898-p
EphA2 (mouse) VsIRLPstsGsEGVP T899-p
EphA2 (rat) VSIRLPSTSGSEGVP T899
S899-p
sIRLPstsGsEGVPF
Upstream
0 86
Treatment
  • EGF
  • metastatic potential
  • SB202190
  • Su11274
EphA2 (human) sIRLPstsGsEGVPF S899-p
EphA2 (mouse) sIRLPstsGsEGVPF S900-p
EphA2 (rat) SIRLPSTSGSEGVPF S900
S901-p
RLPstsGsEGVPFRT
Upstream
0 118
Treatment
  • angiotensin_2
  • EGF
  • metastatic potential
  • SB202190
  • selumetinib
  • Su11274
  • U0126
  • vemurafenib
EphA2 (human) RLPstsGsEGVPFRT S901-p
EphA2 (mouse) RLPstsGsEGVPFRT S902-p
EphA2 (rat) RLPSTSGSEGVPFRT S902
S910-p
GVPFRTVsEWLESIK
0 2
EphA2 (human) GVPFRTVsEWLESIK S910-p
EphA2 (mouse) GVPFRTVSEWLESIK S911
EphA2 (rat) GVPFRTVSEWLESIK S911
Y921-p
ESIKMQQytEHFMAA
Upstream
Downstream
1 30
Effects on Modified Protein
  • molecular association, regulation
Putative in vivo kinases:
  • EphA2 (human)
Treatment
  • Su11274
EphA2 (human) ESIKMQQytEHFMAA Y921-p
EphA2 (mouse) ESIKMQQyTEHFMVA Y922-p
EphA2 (rat) ESIKMQQYTEHFMVA Y922
T922-p
SIKMQQytEHFMAAG
0 15
EphA2 (human) SIKMQQytEHFMAAG T922-p
EphA2 (mouse) SIKMQQyTEHFMVAG T923
EphA2 (rat) SIKMQQYTEHFMVAG T923
Y930-p
EHFMAAGyTAIEkVV
Upstream
Downstream
3 16
Effects on Modified Protein
  • enzymatic activity, induced
  • molecular association, regulation
Effects on Biological Processes:
  • cell differentiation, altered
  • cell motility, induced
Putative upstream phosphatases:
  • PTPRF (human)
EphA2 (human) EHFMAAGyTAIEkVV Y930-p
EphA2 (mouse) EHFMVAGYTAIEKVV Y931
EphA2 (rat) EHFMVAGYTAIEKVV Y931
K935-ub
AGyTAIEkVVQMtND
0 1
EphA2 (human) AGyTAIEkVVQMtND K935-ub
EphA2 (mouse) AGYTAIEKVVQMSNE K936
EphA2 (rat) AGYTAIEKVVQMSND K936
T940-p
IEkVVQMtNDDIkRI
0 3
EphA2 (human) IEkVVQMtNDDIkRI T940-p
EphA2 (mouse) IEKVVQMSNEDIKRI S941
EphA2 (rat) IEKVVQMSNDDIKRI S941
K945-ub
QMtNDDIkRIGVRLP
0 2
EphA2 (human) QMtNDDIkRIGVRLP K945-ub
EphA2 (mouse) QMSNEDIKRIGVRLP K946
EphA2 (rat) QMSNDDIKRIGVRLP K946
Y960-p
GHQKRIAysLLGLKD
Upstream
Downstream
2 69
Effects on Modified Protein
  • molecular association, regulation
Phosphatases, in vitro:
  • ACP1 (human)
Putative in vivo kinases:
  • EphA2 (human)
Treatment
  • gefitinib
EphA2 (human) GHQKRIAysLLGLKD Y960-p
EphA2 (mouse) GHQKRIAySLLGLKD Y961-p
EphA2 (rat) GHQKRIAYSLLGLKD Y961
S961-p
HQKRIAysLLGLKDQ
0 1
EphA2 (human) HQKRIAysLLGLKDQ S961-p
EphA2 (mouse) HQKRIAySLLGLKDQ S962
EphA2 (rat) HQKRIAYSLLGLKDQ S962